HomepageAXGN • NASDAQ
add
AxoGen, Inc Common Stock
$Â 28,65
Na sluitingstijd:(1,08%)+0,31
$Â 28,96
Gesloten: 28 nov, 14:19:20 GMT-5 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 28,55
Dag-range
$Â 28,16 - $Â 28,99
Jaar-range
$Â 9,22 - $Â 28,99
Beurswaarde
1,32Â mld. USD
Gem. volume
894,44K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 60,08Â mln. | 23,51% |
Bedrijfskosten | 44,08Â mln. | 19,94% |
Netto inkomsten | 708,00K | 138,11% |
Netto winstmarge | 1,18 | 130,89% |
Winst per aandeel | 0,12 | 71,43% |
EBITDA | 3,64Â mln. | 159,77% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 35,79Â mln. | 45,91% |
Totale activa | 216,40Â mln. | 12,72% |
Totale passiva | 95,60Â mln. | 3,26% |
Totaal aandelenvermogen | 120,80 mln. | — |
Uitstaande aandelen | 46,12 mln. | — |
Koers-boekwaardeverhouding | 10,90 | — |
Rendement op activa | 2,27% | — |
Rendement op kapitaal | 2,56% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 708,00K | 138,11% |
Operationele kasstroom | 3,22Â mln. | -17,38% |
Kasstroom uit beleggingen | -3,75Â mln. | 24,98% |
Kasstroom uit financiering | 2,39Â mln. | 318,53% |
Nettomutatie in liquide middelen | 1,87Â mln. | 454,08% |
Vrije kasstroom | 3,45Â mln. | -3,94% |
Over
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Opgericht
2002
Hoofdvestiging
Website
Werknemers
452